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Recent advances in molecular genetics have made it possible to 
Understand the molecular mechanisms of human cancer 
progression. The results indicate that clinically evident tumor cells 
already carry multiple genetic alterations and further accumulation of 
genetic alteration occurs during tumor progression. The process of 
carcinogenesis can be divided into the thrgei stages of initiation, 
promotion and progression based on evidence mainly from 
experimental models. However, such processes have been studied 
indirectly in humans by measurements of i«ge-dependent cancer 
incidence. The development of a human cancer probably requires at 
least 5 to 10 different genetic alterations, each assumed to consist of 
the activation of an oncogene or the inastivation of a tumor-
suppressor gene that are able to disrupt strictly controlled cellular 
processes such as differentiation and growth (1,2). 
Lung cancer, although second to prostate cancer in terms of 
frequency, is clearly the number one cause of cancer deaths among 
both males and females. Prognosis is poor with fewer than 13% of all 
lung cancer patients surviving more ihan 5 years after diagnosis. 
Lung tumors arò carcinomas originating from the respiratory 
epithelium and are classified on the basis of histological type. The 
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two main types are small cell lung cancer (SCLC) with few subtypes 
and non-small eel! lung cancer (NSCLC) with a large number of 
subtypes. Small cell lung cancer (SCLC) most probably arises from 
pulmonary neuroendocrine (NE) cells and accounts for about 25% of 
all lung tumors. It is an extremely aggressive neoplasm, is frequently 
associated with distant metastases and has the poorest prognosis of 
all lung tumors. The remaining 75% are non-small cell lung cancers 
(NSCLC) which usually lack the neuroendocrine features that 
characterises the SCLC tumors and are classified according to their 
cell of origin. The NSCLCs include: squamous cell carcinomas which 
may originate from a metastatic squamous epithelium; 
adenocarcinomas which arise in the major bronchi; and large cell 
carcinomas which are predominantly undifferentiated tumors some of 
which may represent their basal or stem cell origin. NSCLC are 
treated primarily with surgery and radiotherapy while SCLC with 
chemotherapy (3). 
The conversion of normal lung stem cells to malignant ones involves 
a series of changes in different set of genes (oncogenes and onco­
suppressor genes). Such a series of events has been demonstrated 
in colorectal carcinoma by Fearon and Vogelstein (4). 
Although in lung cancer the sequential events are not yet 
established, data from different laboratories have focused on the 
following chromosomes, oncogenes and onco-suppressor genes: 
1. CHROMOSOMES 
Several studies have shown alterations in chromosomes 1, 3, 6, 7, 8, 
11, 13, 15, 17 and 19 by RFLP analysis. The most frequent changes 
are deletions in the region p21.3 of chromosome 3 in both NSCLCs 
and SCLCs. This region is believed to encode a yet unknown onco­
suppressor gone (5,6). 
2. ONCOGENES 
2a Type I growth .actor receptors. This group of molecules include 
three transmembrane glycoprotein (c-ert>B-1, c-erbB-2 and o-erbB-
3) related sequences and intrinsic tyrosine kinase activity. It has 
been shown that c-erbB-1 and c-erbB-2 are commonly 
overexpressed in NSCLCs. Overexpression of c-erbB-1 (EGF-r) is 
frequently a result of c-ert>B-1 gene amplification (7-9). 
2b ras gene family. Members of the ras family of proto-oncogenes, 
comprised of K-ras, Η-ras and N-ras, are inner plasma membrane 
associated GTPases that bind GTP to cleave it to GDP. They are 
involved in signa! transduction. Activated ras oncogenes, by point 
mutations in codons 12, 13 and 61 have frequently been detected in 
NSCLCs. There is evidence linking mutations in each member of the 
ras family With'poor prognosis. K-ras is mutated in 30% of 
adenocarcinomas and there is a correlation with smoking history with 
about 30% of smokers compared with 2% of non-smokers having G-T 
transversions at codon 12. This type of mutation is consistent with 
exposure of the lung to carcinogens in tobacco smoke such as 
benzo[a]pyrene (10,11). 
2c mvc. The myc gene family encodes at least three proteins c-MYC, 
n-MYC and I-MYC of MW 62-68 kDa. Gene amplification and 
overexpession of the myc family has been shown to be an important 
feature of SCLCs. It has been postulated that myc amplification 
occurs more frequently in patients who have undergone 
chemotherapy. Amplification of the c-myc gene is found in about 
10% and increased expression in about 50% of NSCLCs of all types 
(12-1-4). 
2d c-raM. The c-raf proto-oncogene located in chromosome 3p14-25 
encodes a serine/ threonine specific protein kinase, p74 which is 
located on the internal side of the plasma membrane, Molecular 
analyses have shown 45% loss of heterozygocity in SCLCs (1). 
2e C-/OS. c-iun. c-fos and c-y'un oncogenes form a complex, AP-1, 
which acts as a transcriptional factor. Recent reports show an 
increased AP-1 activity in NSCLCs. As there is evidence that AP-1 
may be involved in signal transduction, elevated levels may be 
oncogenic. 
2f c-mvb. This proto-oncogene is located on chromosome 6q24 and 
encodes a nuclear transactivator. Recent studies in NSCLCs show 
that aberrant c-myö expression, either deletions or defect RNA 
transcription, may play a role in lung carcinogenesis (1). 
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3. ONCOSUPPRESSOR GENES 
3a P53. The p53 is located in 17q13 chromosome and encodes a 
393bp protein which structurally resembles a transcriptional 
activator factor. p53 functions as a negative regulator of cell growth 
and may play an important role in genomic stability and DNA repair. 
Loss of wild type p53 functions either by mutation, complex 
formation with viral products or cellular negative regulator(s) such as 
the mdm2 gene product, or alteration in subcellular localisation 
removes an Important tumor suppressor mechanism and promotes 
tumorigenesis. 
Mutations in p53 are the commonest genetic changes detected in 
several different types of cancers and are a common feature of 
NSCLCs. The frequency varies with the type of pulmonary cancer 
with about 67% of 5q CLCs and 37% of adenocarcinomas. p53 
mutations carrying G:C—T:A transversions are found in about 50% of 
NSCLCs. This is a type of mutation that may be caused by 
benzo[a]pyrene a potent mutagen found in tobacco known to cause 
this kind of transversions. SCLCs mutations in p53 are present in 
over 75% of cases. p53 alterations have been observed In primary 
tumors as well as in metastases suggesting its early role in the 43 
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pathogenesis of SCLC (15-17). 
3b RB, The Rb-1 protein product, pRB, is a DNA binding protein of 
110 kDa that is thought to be related to events crucial to cell 
division. The cloning and characterisation of the Rb1 gene showed 
that the loss of the gene or its protein product by homozygous 
deletion or mutation was the event that resulted in development. 
There is evidence that the survivors of hereditary retinoblastoma are 
at higher risk for developing lung tumors as adults and to develop 
them at an earlier age than the general population. Relatives of 
retinoblastoma patients who are carriers of an RB-1 mutation have a 
15-fold increased risk of lung cancer the general population (18). 
CONCLUDING REMARKS 
The development of a cancer cell from a normal cell involves a series 
of changes that contribute to a loss of normal growth control 
mechanisms. As far as lung cancer is concerned we are still far from 
understanding the nature of these events. 
Furthermore;; detailed studies are required in order to correlate 
mutations and factors such as diagnosis, clinical parameters, genetic 
predisposition and prognosis. 
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